XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 01, 2021
Jun. 01, 2021
Jan. 05, 2021
Jun. 30, 2022
Jan. 27, 2022
Apr. 30, 2021
Mar. 31, 2021
Jul. 31, 2020
Apr. 17, 2020
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Nov. 27, 2022
Feb. 01, 2022
Commitments and Contingencies (Details) [Line Items]                                  
Employment agreement, description                 The Employment Agreement provided for a base salary of $120,000 and 152,619 of vested shares of the Company’s common stock in April 2020. In addition, Mr. Weisblum shall be eligible to earn a bonus, subject to the sole discretion of the Company’s Board of Directors (“Board”).                
Loan payable                               $ 42,000  
Deferred compensation balance                       $ 21,658          
License fee             $ 10,000 $ 10,000                  
Research and development expenses                   $ 375,795 $ 70,514   $ 651,750 $ 217,962      
Commercial sale term                         10 years        
License agreement expire                         15 years        
Sublicense income, description                         The Company or Company affiliates shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product.        
License agreement, description                         the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b) $50,000 on or before the first anniversary of the effective date, which was paid in February 2022. The license fee is non-refundable and is not creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on February 17, 2021 and $50,000 in February 2022 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization expense of $4,375 in 2021. During the nine months ended September 30, 2022, the Company recognized amortization expense of $3,750. On December 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $15,625. On September 30, 2022, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $61,875 as reflected in the accompanying condensed consolidated balance sheets.        
Royalty payments, description                         Royalty Payments Terms:  (i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and   (ii)5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and          
Prepaid expense and other current assets                   833     $ 833   $ 838    
Prepaid expenses non-current                   10,410     10,410   $ 11,034    
Non-refundable cash payment     $ 500,000                   $ 500,000        
Net sale percentage                         2.00%        
Licensor share (in Shares)     500                   500        
Aggregate of converted shares (in Shares)     625,000                   625,000        
Revenue term     15 years                   15 years        
Number of voting shares (in Shares)                             20,000    
Reverse stock split vote, description                         In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date that the Reverse Stock Split Vote is approved by Aikido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of Aikido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment.Prior to the April 12, 2021, issuance of the common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred stock which was equivalent into Aikido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of Aikido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.        
Deferred revenue                   1,031,250     $ 1,031,250        
Cash received                   500,000     500,000        
Securities received                   531,250     531,250        
Recognized revenues                         51,562   $ 68,750    
Deferred revenue current portion                         68,750   68,750    
Deferred revenue long-term portion                         41,620   893,750    
Revenue long term portion amounts                   842,187     $ 842,187        
Consideration fee payable percentage                         110.00%        
Upfront license fees           $ 50,000             $ 50,000        
First commercial sale                         10 years        
Agreement shall expire                         15 years        
Sponsored study agreement, description     The total cost under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized the prepaid expense of $40,737.                            
Sublicense amount paid   $ 342,850                              
Sponsored research agreement, description   The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement on June 15, 2021, the second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021, the third payment of $60,570 on March 1, 2022 and a fourth payment of $60,570 in August 2022, which were recorded to prepaid expense and other current assets – current to be amortized over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense.                              
Company paid cash $ 92,095                                
Company paid second payment                                 $ 92,095
Prepaid expense                   215,412     $ 215,412   359,021    
Prepaid expense related to research                         287,217   $ 71,804    
Payment of university                         5,000        
Agreement, description                             In 2021, the Company paid $5,000 related to this agreement. During the nine months ended September 30, 2022, the Company paid $15,000 related to this agreement.    
Minimum [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Salary was increased                   120,000     120,000        
Maximum [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Salary was increased                   $ 180,000     180,000        
Third Amendment [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Research and development expenses       $ 2,500                          
Master License Agreement [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Upfront license fees                         $ 1,900,000        
JV Agreement [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Pursuant terms, description                         Pursuant to the terms of the JV Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture.        
Dr. James Kuo [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Employment agreement, description         James Kuo entered into an employment agreement (“Kuo Employment Agreement”) for Dr. Kuo to serve as the Vice President of Research & Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days prior to the applicable renewal date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (“Board”) and shall be payable at the Company’s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.                        
Stock option (in Shares)                         16,000        
Fair value of stock option                         $ 94,915        
Risk free interest rate                         1.18%        
Expected dividend yield                         0.00%        
Expected term                         2 years        
Expected volatility                         117.00%        
Fair value of the unvested stock option                         $ 95,915        
Stock-based Compensation                         73,257        
Deferred compensation balance                         $ 21,658        
Aikido [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Deferred revenue current portion                             $ 3,352    
Deferred revenue long-term portion                             44,134    
Columbia University [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Sponsored research agreement, description                         The Company paid the first payment of $430,825 in November 2021 and the second payment of $430,825 in July 2022, which were recorded to prepaid expense and other current assets – current to be amortized over the estimated project timeline of twelve months. On October 13, 2022, the Company entered into an amendment to the Columbia Agreement (the “Columbia Amendment”), pursuant to which the parties agreed to extend the payment schedule, whereby the third payment of $430,825 is due in March 2023 and the remaining payment of $143,607 is due upon completion.        
Sublicense Agreement [Member]                                  
Commitments and Contingencies (Details) [Line Items]                                  
Sublicense income, percentage           25.00%                      
Sublicense agreement amount paid           $ 12,500                      
Recognized amortization expenses                             628    
Amortization expense                       $ 629          
Deferred revenue current portion                         $ 3,352        
Recognized revenues                         $ 2,514   $ 2,514